SCHEMBL4095825

SCHEMBL4095825

O=c1c(-c2ccccc2Cl)cc2cnc(NC3C4CN(S(=O)(=O)c5cccs5)CC43)nc2n1C1CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.45
MAPK14 Q16539 1/20 0.45
CCND1 P24385 10/20 0.42
CCNE1 P24864 10/20 0.42
CDK2 P24941 10/20 0.42
CDK6 Q00534 10/20 0.42
CCNT1 O60563 2/20 0.42
CDK4 P11802 2/20 0.42
CDK9 P50750 2/20 0.42
CCND3 P30281 1/20 0.42
TNK2 Q07912 3/20 0.40
PAK1 Q13153 1/20 0.39
RIPK2 O43353 1/20 0.39
ACVR1 Q04771 1/20 0.39
NOD2 Q9HC29 1/20 0.39
SIK1 P57059 1/20 0.39
SIK2 Q9H0K1 1/20 0.39
SIK3 Q9Y2K2 1/20 0.39
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084266 0.89 LCK (0.56) LCKMAPK14PAK1RIPK2ACVR1
SCHEMBL4095478 0.88 LCK (0.48) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4084205 0.86 CCND1 (0.54) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4089878 0.86 LCK (0.51) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4101334 0.85 LCK (0.47) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4088976 0.85 LCK (0.44) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4094501 0.83 LCK (0.57) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4089113 0.82 LCK (0.45) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4094757 0.81 LCK (0.50) LCKMAPK14CCND1CCNE1CDK2
SCHEMBL4094247 0.80 LCK (0.53) LCKMAPK14CCND1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US claimed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP claimed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO claimed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-05-21 US disclosed
EP-1831215-A1 PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2007-09-12 EP disclosed
WO-2006056863-A1 PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131430-A1 PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS TLR1, TPMT, NOD1 LCK 568/4885MAPK14 3185/4885CCND1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.